NCT04428762View on ClinicalTrials.gov

Glycemic Control and Quality of Life With i- Port Advance in Pediatric T1DM

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 1, 2020

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
T1DM
Interventions
DEVICE

I-Port Advance use

participants will apply I-port advance for 4 weeks and will inject all insulin through the port. follow up 3 months with/ without i-port.

Sponsors

Collaborators (1)

Kaplan Medical Center
All Listed Sponsors
collaborator

Sheba Medical Center

OTHER_GOV

collaborator

Kaplan Medical Center

OTHER

collaborator

Soroka University Medical Center

OTHER

collaborator

Wolfson Medical Center

OTHER_GOV

collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

lead

Assaf-Harofeh Medical Center

OTHER_GOV

NCT04428762 - Glycemic Control and Quality of Life With i- Port Advance in Pediatric T1DM | Biotech Hunter | Biotech Hunter